Preparation and Evaluation of Modified Chitosan Nanoparticles Using Anionic Sodium Alginate Polymer for Treatment of Ocular Disease
Mucoadhesive nanoparticles offer prolonged drug residence time at the corneal epithelium by adhering to the mucous layer of the eye. Here, in this research investigation, voriconazole-loaded chitosan mucoadhesive nanoparticles (VCZ-MA-NPs) were modified to mucous-penetrating nanoparticles (VCZ-MP-NPs) by coating them with anionic polymer sodium alginate. The ionic gelation method was utilized to prepare mucoadhesive chitosan nanoparticles, which were further coated with sodium alginate to obtain the surface properties essential for mucous penetration. The developed VCZ-MA-NPs and VCZ-MP-NPs were evaluated extensively for physicochemical delineation, as well as in vitro and ex vivo studies. The particle size, polydispersity index, and ζ potential of the VCZ-MA-NPs were discovered to be 116 ± 2 nm, 0.23 ± 0.004, and +16.3 ± 0.9 mV, while the equivalent values for VCZ-MP-NPs were 185 ± 1 nm, 0.20 ± 0.01, and −24 ± 0.9 mV, respectively. The entrapment efficiency and drug loading were obtained as 88.06%±1.29% and 7.27% ± 0.95% for VCZ-MA-NPs and 91.31% ± 1.05% and 10.38% ± 0.87% for VCZ-MP-NPs, respectively. The formulations were found to be stable under different conditions (4 °C, 25 °C, and 40 °C). Chitosan nanoparticles and modified nanoparticles showed a spherical and smooth morphology under electron microscopic imaging. An excised caprine cornea was used for the ex vivo permeation study, exhibiting 58.98% ± 0.54% and 70.02% ± 0.61% drug permeation for VCZ-MA-NPs and VCZ-MP-NPs, respectively. The findings revealed that the mucous-penetrating nanoparticles could effectively pass through the corneal epithelium, thus overcoming the mucous barrier and fungal layer of the eye, which highlights their potential in the treatment of fungal keratitis.
Top-30
Journals
|
1
2
3
|
|
|
Journal of Drug Delivery Science and Technology
3 publications, 9.68%
|
|
|
Pharmaceutics
3 publications, 9.68%
|
|
|
Drug Discovery Today
2 publications, 6.45%
|
|
|
Nanomedicine
2 publications, 6.45%
|
|
|
Drug Delivery and Translational Research
2 publications, 6.45%
|
|
|
AAPS PharmSciTech
1 publication, 3.23%
|
|
|
Molecular Pharmaceutics
1 publication, 3.23%
|
|
|
International Journal of Biological Macromolecules
1 publication, 3.23%
|
|
|
ACS Infectious Diseases
1 publication, 3.23%
|
|
|
Colloids and Interface Science Communications
1 publication, 3.23%
|
|
|
International Journal of Pharmaceutics
1 publication, 3.23%
|
|
|
Current Eye Research
1 publication, 3.23%
|
|
|
Russian Chemical Reviews
1 publication, 3.23%
|
|
|
Green Materials
1 publication, 3.23%
|
|
|
Biomedical Materials (Bristol)
1 publication, 3.23%
|
|
|
Drug Metabolism and Bioanalysis Letters
1 publication, 3.23%
|
|
|
BioNanoScience
1 publication, 3.23%
|
|
|
Therapeutic Delivery
1 publication, 3.23%
|
|
|
Current Nanomedicine
1 publication, 3.23%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
|
|
|
Elsevier
10 publications, 32.26%
|
|
|
Springer Nature
6 publications, 19.35%
|
|
|
Taylor & Francis
4 publications, 12.9%
|
|
|
MDPI
3 publications, 9.68%
|
|
|
American Chemical Society (ACS)
2 publications, 6.45%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 6.45%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.23%
|
|
|
Emerald
1 publication, 3.23%
|
|
|
IOP Publishing
1 publication, 3.23%
|
|
|
2
4
6
8
10
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.